XNAS · ACTU
+2.68% · +$0.0300 · Vol 176.6K
After hours · updated 16:54:43 ET
Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc. Common stock

PHARMACEUTICAL PREPARATIONS
$1.15
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
ACTU
Actuate Therapeutics, Inc. Common stock
Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

50/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ACTU moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ACTU catalysts
About Actuate Therapeutics, Inc. Common stock
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
12
Country
US

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.12
Day high
$1.22
Day low
$1.07
Previous close
$1.12
52W high
$8.72
-86.81% from high
52W low
$1.06
1% of range
Market cap
$26.8M
EPS
$-1.1100
Beta
1.79
Shares out
23.9M
Volume
176.6K
0.48× rel vol
Avg volume
371.7K
VWAP
$1.14
Price history computed in-house
1W
+6.48%
1M
-17.86%
3M
-65.57%
1Y
-84.27%
YTD
-81.21%
SMA 50 $1.63 · below
SMA 200 $3.90 · below
52W position 1%

ACTU overview

Veridion Score
50
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ACTU.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ACTU Form 4 filings
Public disclosures

Congress activity in ACTU

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ACTU in the cached public ledger.

Federal contracts

ACTU contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ACTU in this window.
Lobbying spend

ACTU lobbying filings, year to date.

Registered lobbying filings matched to Actuate Therapeutics, Inc. Common stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ACTU in this window.
Loading news for ACTU
Analyst ratings
Sovereign unlock shows live analyst consensus for ACTU.
Options
Sovereign unlock shows live options positioning for ACTU.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.